INTRODUCTION
Since 1989 there has been an exponential increase in the number of antiepileptic drugs (AEDs) used to treat patients with epilepsy, in general, and those with partial epilepsy in particular. In addition to the five firstgeneration AEDs (carbamazepine, phenobarbital, phenytoin, primidone, and valproate), there are ten second-generation AEDs (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, vigabatrin, and zonisamide) and four third-generation AEDs (eslicarbazepine acetate, lacosamide, retigabine, and perampanel). In addition, there are two orphan AEDs (rufinamide and stiripentol), which are licensed for the treatment of specific 'difficult to treat' epilepsy syndromes.
Despite the hype, new AEDs have so far had minimal impact on the prognosis of intractable partial epilepsy in adults. Thus, whilst 63% of patients achieved seizure freedom in a cohort of patients with newly diagnosed epilepsy in 2000 [1] , only 5% more achieved seizure freedom 12 years later, despite the introduction of many new AEDs [2] . These new AEDs, however, are associated with improved adverse effect profiles and pharmacokinetic characteristics, particularly a reduced propensity to pharmacokinetic interactions, compared with early AEDs [3] .
Recently a new AED, perampanel with a firstin-class mechanism of action, was approved in Eighty-nine publications were selected on the basis of meeting the above inclusion criteria. Primary sources were preferred, but review articles were used in the absence of a primary reference. Data contained in summary of product characteristics (SPCs) were used whenever a published article was not available.
DISCUSSION

Partial epilepsy
Functionally seizures are divided into partial and generalized subtypes. Partial, or focal-onset seizures as they are also known, are thought to originate in a network of connections that facilitate seizure propagation constrained to one cerebral hemisphere [4] . This contrasts with the concept of generalized seizures, which are believed to rapidly engage a network involving both hemispheres [4] . Partial seizures may be simple seizures involving one area in a hemisphere, for example an isolated motor seizure, or can be more complex; there may be alternative networks of propagation through the hemisphere or networks that cross to involve both hemispheres giving rise to secondary generalized seizures.
Partial epilepsy is a diverse category. This is reflected by prevalence estimates, which vary markedly depending on the study population.
Twenty-five separate studies have looked at the relative prevalence of partial and generalized epilepsy [5] . In Europe, partial epilepsy accounts for between 18% and 63% [6, 7] of cases, and in North America the figure varies from between 12% and 59% [8, 9] . The large variation in these figures is thought to reflect differences in partial epilepsy classification and study design between publications. 
Current Management of Partial Epilepsy
Refractory Partial Epilepsy
In the past, the definition of refractory or drugresistant epilepsy varied widely in the academic literature. Only in 2010 did the ILAE propose a consensus statement defining drug-resistant epilepsy as 'failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom' [13] . A long-term follow-up study of 1,098 patients, who initially started treatment in Scotland, identified that failure of seizure freedom despite multiple AEDs occurs in up to 30% of patients with epilepsy [2] . Of the total study population, 49.5% of patients became seizure-free on their first AED, a further 13.3% on their second, 3.7% on their third, and successively smaller amounts when subsequent AEDs were trialed either as monotherapy or adjunct.
The typical pathway if monotherapy fails is to continue the AED that has proven most successful and add an adjunct. Cochrane reviews have demonstrated that clobazam [14] , eslicarbazepine acetate [15] , gabapentin [16] , lamotrigine [17] , levetiracetam [18] , oxcarbazepine [19] , tiagabine [20] , topiramate [21] , vigabatrin [22] , and zonisamide [23] are all effective as adjunctive treatment of refractory partial seizures. However, there is little guidance from published literature as to what order these agents should be trialed, but many look to combinations with different mechanisms of action. What is known is that the actual placebo-corrected efficacy for AEDs as adjuncts is small [24, 25] . A large meta-analysis incorporated the results of 54 studies, involving 11,106 patients [25] , and demonstrated that, after correction for placebo, AEDs used as an adjunct in refractory epilepsy resulted in seizure freedom in only 6%, and reduced seizure frequency by more than 50% in only 21% of patients.
In patients with epilepsy who have failed to respond to pharmacologic treatment surgery can be considered. Only a minority of patients are suitable. Surgery may range from a minimally invasive procedure, for example, insertion of a vagal nerve stimulator, to invasive intracranial surgery. The success rate varies depending upon the procedure: 66% of patients with temporal lobe resections will become seizure-free long term, whilst for subpial transections, the likelihood of seizure freedom is only 16% [26] .
Perampanel
Mechanism of Action
The pathophysiology of seizure generation remains poorly understood. Essentially, a seizure represents an imbalance between neuronal excitation and inhibition. Synaptic concentrations of excitatory neurotransmitters such as glutamate rise, whilst inhibitory neurotransmitters such as gammaaminobutyric acid (GABA) fall [27] .
Continuing with this simplification, current AEDs can be broadly divided into two groups:
agents that act to inhibit excitatory mechanisms and those that act to promote inhibitory mechanisms [27] All studies demonstrated a significant improvement in median change in seizure frequency with 4-12 mg/day perampanel. However, only two studies (305, 306) [38, 39] showed a significant improvement in responder rate versus placebo (Table 2) . A dose-dependent increment in responder rate and a median percentage change in seizure frequency were seen over 4-8 mg/day doses. Doses of 2 mg/day had no significant effect compared with placebo [39] . Compared with 8 mg/day doses, 12 mg/day had no increased effect in responder rates [37, 38] and showed an improvement in median percentage seizure frequency rates in only one of the two studies (305) that investigated perampanel at this higher dose [38] . Study 304, in which 12 mg/day perampanel failed to make a difference in median percentage seizure frequency, also failed to show a change in responder rate at any dose compared with placebo.
Several explanations have been suggested for the lack of significant change in responder rate with perampanel in Study 304. French and colleagues proposed that the lack of impact may be due to: (1) the fact that the responder rate has a lower sensitivity when compared with median change in seizure frequency rendering significant differences harder to establish, or (2) the findings of Study 304 may have been skewed by its inclusion of Central and South American patients, who had a substantially higher placebo responder rate than the North American population, with some speculation as to whether the diagnosis of epilepsy was correct for some of these patients and if socio-economic factors played a part in the high placebo response [39] . Further analysis suggested that if one looked at just the North American group, then the responder rate at 8 and 12 mg/day of perampanel differed significantly from placebo.
This suggests problems with the implementation of the study in Central and South America. There do not appear to be any substantial differences in patient selection. In both studies 304 and 305, the proportion of patients with partial and complex partial seizures, the number of concomitant AEDs at baseline, baseline seizure frequency, and median time since diagnosis of epilepsy were similar. and 306, demonstrated that the reduction in seizure frequency with perampanel was sustained long term (median duration of perampanel therapy of 51.4 weeks) [41] .
However, the lack of placebo and no limitation on any additional AEDs added after the completion of the original phase III studies render this study difficult to interpret with regard to long-term efficacy.
Treatment-Related Adverse Events Discontinuation from perampanel phase III clinical trials occurred in 6-19% of patients as a result of treatment-related adverse events (TRAEs). These events were dose dependent ( Table 2 ). The majority of TRAEs were classified as mild-moderate with very few studies identifying severe events. The most common TRAEs in all trials, including extension studies, were dizziness, fatigue, headache, and somnolence [37] [38] [39] [40] [41] . The former three events in particular occurred in a dose-dependent fashion. The adverse events that most frequently resulted in cessation of perampanel or dose-reduction were ataxia, dizziness, convulsion, fatigue, headache, and vertigo [37] [38] [39] . None of the studies demonstrated a significant worsening of seizures compared with placebo, and only one case of sudden unexpected death in epilepsy occurred [42] . There were no deaths directly related to perampanel treatment. Weight increases of up to *2 kg were experienced with the highest doses of perampanel.
Psychiatric
Adverse Events The most commonly reported behavioral TRAE was aggression. This increased in a dose-dependent fashion with 12 mg/day doses resulting in aggression in up to 3.1% of patients, but resulting in cessation of therapy in only one case [42] . Although the data set is small, aggression appeared to be more common in adolescents (n = 22, 18.2%) than in the overall population (n = 53, 4.5%). Three adolescent patients (2.5%) and 13 adult patients (1.1%) withdrew due to aggression. Aggression was severe in 3 adolescents (2.5%) compared with 8 patients in the overall population (\1%).
Reported adverse events were low and similar to placebo with regard to suicidality and other behavioral disorders. These tended to occur in patients with a strong personal history of mental health disorder and other potentially precipitating factors were normally identified, for example, recent cessation of risperidone in one patient. [43, 44] ; this can be reduced to *25 h with strong enzyme inducers, e.g., carbamazepine. Seventy percentage of a perampanel dose is excreted in feces, the rest by the renal system [45] . Only *2% of an administered dose is excreted as unchanged perampanel in urine.
Pharmacokinetic Profile
The usual dosage of perampanel is 4-12 mg/ day. There is, however, as yet no trial data comparing perampanel with alternative AEDs. Neurol Ther (2013) 2:13-24 23
